Advantages of and problems with short-term mutagenicity tests for the assessment of mutagenic and carcinogenic risk. by Ramel, C
Environmental Health Perspectives
Vol. 47, pp. 153-159, 1983
Advantages of and Problems with
Short-Term Mutagenicity Tests for
the Assessment of Mutagenic and
Carcinogenic Risk
by Claes Ramel*
The Salmonella microsomal assay has become an indispensible tool for the screening of
mutagens and carcinogens, particularly when a large number of samples have to be tested, as in
the present context for the screening ofair pollution. However, for a more definite identification
of potential carcinogens, a verification of the results from bacterial tests has to be performed
with a battery of other tests, including point mutations and chromosomal aberrations in
eukoaryotic systems.
While there is a close qualitative correlation between the mutagenic and carcinogenic property
ofchemicals, a corresponding quantitative correlation between the mutagenic and carcinogenic
potency is not always found. One reason for this lack of quantitative correlation presumably
depends on the fact that cancer is induced in two steps, ofwhich only the initiating, but not the
promoting, step constitutes a mutational event, which is reflected by mutagenicity tests.
Present mutagenicity tests have concentrated on discrete major mutations, while mutations of
polygenes, acting on quantitative characters, have largely been omitted. Mutational data from
Drosophila indicate, however, that polygenes mutate at a considerably higher rate than major
genes and that they have a comparatively strong effect in heterozygous condition. It seems of
great importance to develop appropriate methods to study induced mutations of polygenic
systems and to get a better understanding of the properties of these genetic systems and an
evaluation of the risk connected with induced mutations in polygenes.
Introduction
An epidemiological approach to detect chemicals
in the environment which cause cancer and heredi-
tary defects has serious limitations. Only about 25
chemicals have been recognized as human carcin-
ogens. At the same time, the variation in cancer
frequency between human populations indicates
that the vast majority of human cancer is induced
by environmental factors. When it comes to the
detection of hereditary effects of chemicals, the
situation is even more questionable. There are no
fully established cases ofinduced hereditary defects
transmitted to the offspring in humans.
There is, however, no reason to believe that this
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meagre result ofepidemiological investigationsreally
reflects the actual situation in human populations.
It rather is the inevitable result of the immense
difficultiesinheritedinthesestudies, suchaslatency
periods ofdecades, a considerable background level
of traits under investigation and a multistep pro-
cess for tumor induction in which combinations of
exogenous andendogenousfactorsmaybeinvolved.
It is therefore quite obvious that we have to rely
on experimental rather than epidemiological data
for the detection ofchemical mutagens and carcino-
gens in our environment. The most reliable exper-
imental data for extrapolation to humans can be
expected from mammalian systems, but unfortu-
nately experiments with mammals also have seri-
ous limitations. Tumor induction experiments in
mice take 2-3 years and cost somewhere around
$200,000 for one test. Even a massive researcheffort with animal cancertests would not be enough
for the screening of thousands of chemicals and
chemical mixtures in the human environment.
The Foundation for
Short-Term Tests
The way out ofthis dilemma has been the use of
short-termmutagenicityteststodetectboth carcin-
ogenic and mutagenic chemicals. This technology
is based on two assumptions. The first one is that
the ultimate cause ofcancer can be brought back to
some mutational changes in DNA. Although this
still is a hypothesis, there is a wealth of data
supporting it: Namely, malignancy is essentially an
irreversible trait transmitted from one cell genera-
tion to the next. Tumors have a monoclonal origin,
that is, they emanate from one single cell. At least
the vast majority of known carcinogens and muta-
gens share an electrophilic property and binding to
nucleophilic centers in macromolecules including
DNA. With few exceptions, carcinogens have been
shown to induce mutations. Animpairment ofDNA
repair leads to an increase ofcancer. Cell transfor-
mation by oncogenic virus implies a change at the
DNA level.
The second assumption behind the use of short-
term mutagenicity tests is the similarity of the
genetic code and protein synthesis between organ-
isms, which would allow extrapolation between
species. The foundation for that is firm enough, but
in real life extrapolations between species for
mutations meets a number of other problems.
The chemical induction of mutations and cancer
involves several steps, which have to be taken into
account for any testing procedure. Before discuss-
ingthe actual test systems it may be appropriate to
summarize the course of events for mutations and
the complications met with.
The problems in chemical induction ofmutations
can be considered at three levels: the uptake ofthe
chemical; the biotransformation in the organism;
the induction of mutations.
The first level-the uptake of the chemical
implies amajorproblem inthe present context with
car exhausts and air pollution. The genetically
active compounds are largely bound to particles,
but there are widely different opinions as to the
availability ofsuch particle bound compounds when
they are inhaled and are taken up by macrophages.
The second level ofcomplication is indeed amajor
one and somewhat of a bottleneck in general for
extrapolation of experimental data. Most carcino-
gens require an activation for their carcinogenic
effect, mostly by means of the mixed function
oxidase system with cytochrome P-450. The capac-
ity for such an activation of promutagens varies
considerably between species, tissues and individu-
als, but the liverusually constitutes the most active
tissue in this respect. There is, however, also an
intricate balance between activation and subse-
quentinactivationofreactivemetabolites, forinstance
by conjugation and this balance also varies between
tissues.
Even if a mutagenic chemical which enters the
body or is formed through biotransformation reacts
with DNA, this does not automatically lead to a
mutation. The organism has at its disposal a com-
plicated series ofrepairsystems, which functions as
a final barrier against unwanted DNA alterations.
A deficiency in the repair system may lead to
serious defects and cancer, as illustrated by Xero-
derma pigmentosum in humans, which is deter-
mined by a recessive gene, eliminating excision
repair. Alsoheterozygotes mayhaveahighercancer
incidence than normal. In some cases the localiza-
tion of tumors can be brought back to the normal
variation between tissues in DNA repair. Ethyl-
nitrosourea thus causes tumors in the brain but not
the liver, apparently because the liver but not the
brain can repair the mutagenic alkylations (1).
Finally the interaction of chemicals with the
geneticmaterialresults indifferenttypes ofgenetic
alterations-point mutations, which imply changes
at the nucleotide level, and chromosome aberra-
tions. Furthermore, changes in the number of
chromosomes can occurbyinteractions ofchemicals
with the spindle fiber mechanism. Chemicals acting
on the spindle fibers do not have to be strictly
mutagenic that is, interacting with DNA.
Short-Term Test Systems
Salmonella Assay
There obviously are severalfactors which have to
be considered when applying short-term tests for
the screening of mutagens and carcinogens. First-
ly, mutation induction is generally a rare event, no
matter what, and a major problem in mutagenicity
screening is the resolving power of the test. For
pointmutations, microorganisms constitute anideal
material from that point of view. Millions of indi-
viduals can be scored in a short time. On the other
hand, microorganisms do not meet a second require-
ment-thatis, arelevantbiotransformation ofchem-
icals. This problem has beentackled successfullyby
the additionofamammalianmetabolizing system to
microorganisms, in most cases Salmonella. The use
ofSalmonella formutagenicity tests is based on the
154 C. RAMELSHORT-TERM MUTAGENICITY TESTS
researchbyAmesonthebiochemistry, organization
and operation of the histidine locus in Salmonella
(2,3). The test system rests on the use ofmutations
in the histidine locus, which implies that the bacte-
ria cannot synthesize histidine and therefore do not
grow on ordinary medium lacking histidine. Only
those few bacteria which have mutated back to
normal will be able to grow, and the number of
colonieswillreflectsuchreversemutations. Aseries
ofSalmonella strains were synthesized with defined
mutational changes in the histidine locus exchanges
of single bases in DNA (base substitutions) and
addition or deletion ofbases (frame shift). Reverse
mutations to histidine independence require the
same type of base changes, that is, base substitu-
tion and frame shift. By using different strains of
bacteria in the testing, one can therefore establish
the actual mutagenic mechanism of the test com-
pound.
Othermutations have been introduced in orderto
increase the sensitivity ofthe test system. Thus, a
large part of error-free repair has been excluded,
and also the lipopolysaccharide envelope has been
reduced to facilitate the penetration of chemicals
into the bacteria and make them more like mamma-
lian cells. Finally, a plasmid has been introduced,
which greatly increases the sensitivity to some
chemicals by increasing error prone repair. Two
strains with this plasmid, TA 98 for frame shift and
TA 100 for base substitutions, have become the
most extensively used Salmonella strains; as we
will see during this symposium, most mutagenicity
screening ofair and exhaust samples are performed
with TA 98 and to some extent TA 100.
The requirement of a high resolving power for
mutations has no doubt been fulfilled with Ames
Salmonella strains, but the problem ofbiotransfor-
mation still remains. Salmonella and other bacteria
do not have the metabolic capacity ofmammals. In
order to imitate the conditions in the mammalian
body one adds a mammalian liver fraction usually
from rats. This liver fraction, the S9 mix, contains
the microsomal enzymes responsible for the major
activation of indirect mutagens and carcinogens.
This combination ofSalmonellatester strains with a
metabolizingliverfractionconstituteswhatiswidely
known as the Salmonella microsomal assay orAmes
test. The sensitivity and the accuracy ofthis assay
has made it the principle system for mutagenicity
testing. One important reason for this is the close
qualitative correlation between mutagenicity in Sal-
monella tests and animal carcinogenicity. Correla-
tions of close to 90% were reported from various
investigations (4-6). Rinkus and Legator (7) have
pointed out, however, that certain classes of car-
cinogens are not detected as efficiently, and in their
survey, which included such chemicals, the correla-
tion between mutagenicity and carcinogenicity was
only 75%. Among the classes giving a low response
inthe Ames testare chlorinated organic compounds,
such as DDT, PCB, TCDD, chloroform and carbon
tetrachloride. It has been suggested by Ames that
these compounds act by mechanism otherthan elec-
trophilic reaction, namely, by means ofradical for-
mation, probably through lipid peroxidation (8).
Ames has recently constructed new strains which
react on alteration ofA-T base pairs instead ofthe
ordinary change ofC-Gbase pairs (8). These strains
are sensitive to peroxides and presumablymay pick
up chemicals acting by radical formation.
Tests on Higher Organisms
Although this Salmonella assay has become a
standard procedure formutagenicity testing, it can-
not be used in isolation for risk identification. It
must be supplemented with other test systems.
There are several reasons for that. Firstly, Salmo-
nella and other microorganisms can only measure
point mutations but not chromosome aberrations or
changes in chromosome number. Secondly, the
reverse mutation system in Salmonella measures
specific DNA changes, but not all types of point
mutations may be covered. A forward mutation
system, that is, mutations from a functional to a
nonfunctional condition of a gene, can be expected
to cover all possible genetic changes, which can
inactivate the genes. Thirdly, although the genetic
code and the protein synthesis are universal, the
organization ofthe chromosomes and theregulation
of the gene action differ widely between microor-
ganisms and higher organisms. Fourthly, the met-
abolic system added in vitro constitutes a highly
simplified system, and among other problems it
does not take into account the balance between the
activating and deactivating capacity ofthe metabo-
lism in vivo. The liver S9 mix has the tendency to
overestimate the activation of procarcinogens and
isthereforesomewhat"overpessimistic", whichmay
be an advantage, however, for a prescreening pro-
cedure.
For a more reliable risk identification of muta-
genic and carcinogenic chemicals it is therefore
necessary to use a battery ofshort-term tests. The
supply of possible test systems is indeed huge-a
recent survey recognized 116 different tests (9).
However, only a few can be considered sufficiently
established for practical purposes. The time does
not permit me to discuss these test systems, but I
will just mention some important types of tests
(10-12).
Beside a number ofbacterial systems, which are
155used as replacement and complement to Salmonel-
la, mammalian cell cultures, including human cells,
are probably the most widely used screening sys-
tems. The mutation assay with the HGPRT locus,
giving rise to resistance to the purine analogs
8-azaguanine or 6-thioguanine, has been the most
common system used. Other systems are resistance
to ouabain and diphtheria toxin and forward muta-
tions in the TK (thymidine kinase) locus. An impor-
tant advantage ofthese cell culture systems, beside
the fact that they measure effects in mammalian
cells, is the fact that they are based on forward
mutations and thus cover a wide spectrum ofmuta-
genic lesions.
A very important aspect of mammalian cell cul-
tures is the fact that they can be used to study
severalothergenotoxicendpoints, chromosome aber-
rations, nondisjunction, primary DNA damage and
neoplastic transformation.
It may be mentioned that many chemicals are
specifically toxic to bacteria and this toxicity may
totally mask a mutagenic effect. As an example,
emission samples from some powerplants run on oil
and coal studied by Alfheim and M0ller were nega-
tive in Salmonella, but also highly toxic. Jenssen at
our laboratory got clear positive effects, however,
on the same material with hamster cells (13). In
case ofbactericidal samples cell cultures often con-
stitute an appropriate substitute to bacterial sys-
tems.
It should be pointed out that most mammalian
cell cultures used for mutation work have lost most
or all of their metabolic capacity and metabolic
systems have tobe added as forbacteria. As empha-
sized before, the biotransformation ofchemicals is a
bottleneck, particularly for in vitro tests. The addi-
tion of a microsomal fraction of mammalian liver
has implied a very important improvement, but it
must be realized that this does not mimic the situa-
tion in real life. In vitro tests can, however, be
combined with a more complete and relevant meta-
bolic system. At our laboratory we have developed
a useful system with in vitro perfusion of rat liver
combined with mammalian cells or Salmonella as
indicators of mutations (14,15).
The problems concerning biotransformation of
chemicals can ofcourse to a great extent be solved
by using in vivo tests on mammals. Unfortunately,
such tests are not nearly as efficient experimentally
as in vitro tests on cells or bacteria and the resolv-
ing power for point mutations is very low and the
costs high. For chromosome aberrations, however,
a large number of cells can be studied from one
animal and such in vivo test on mammals can there-
fore be used as a routine protocol. Particularly the
formation of micronuclei in bone marrow cells is a
very sensitive, rapid and cheap system for measur-
ing chromosome breakage and effects on chromo-
some distribution (16).
For the very important group ofmutations in the
germ line, giving rise to hereditary effects, mam-
malian test systems are far from optimal, although
such tests can be performed, particularly on mice,
by means of specific locus, translocation and domi-
nant lethal tests. One useful test system in this
connection is the fruitfly, Drosophila. Being the
genetically best mapped and studied higher organ-
ism, many sensitive and sophisticated test systems
are available. A very important point here is that
Drosophila has the mixed function oxygenase sys-
tem with P-450 forthe activation ofprocarcinogens.
This system is furthermore particularly well devel-
oped in spermatides, which make male germ cells
sensitive and useful for the screening of chemical
carcinogens and mutagens (17).
Testing Strategies
Several test systems are required for a risk
identification of chemicals, but the tests can be
combined according to different strategies. There
are primarily two different ways of performing
such tests, either using a battery of tests more or
less simultaneously or else using a sequence of
testing, a "tier" system. For certain chemicals, like
food additives and drugs, the recognition ofa muta-
genic and carcinogenic potential has to be done with
maximum accuracy already from the beginning,
and a battery of tests is required no matter what.
When one is dealing with a large number of sam-
ples, as is the usual case with industrial chemicals
and emission samples, the limited testing facilities
make it necessary to performthe tests in successive
steps or tiers, starting with the most sensitive
system, which usually is the Salmonella assay. A
verification of positive results in the first tier is
done at a second tier with more sophisticated and
more relevant test systems, such as mammalian
tests in vitro and in vivo, Drosophila, etc. A third
testing level should aim at a quantification of the
genotoxic risk identified in previous tests.
The usefulness of such a sequential testing pro-
cedure with a first screening by means ofbacterial
systems has been shown in numerous instances.
Particularly illustrative are the investigations by
Sugimura and his group. The bacterial tests consti-
tuted the primary tool to recognize the mutagenic
potential of pyrolysis products of food items and
this lead to the fundamental discovery and struc-
ture determination of super mutagenic amino acid
pyrolysis products (18). Also the first recognition of
the carcinogenicity ofthe inJapan widely used food
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preservative AF 2 can be brought back to bacterial
tests in Japan (19).
It is no coincidence that we will during this
conference over and over again deal with bacterial
test results. Because of the large scale and the
complexity of air pollution, much of the testing
remained at the tier 1 level with bacterial tests.
However, the broad approach with various test
systems by the EPA program constitutes an impor-
tant exception. It is to be hoped that a wider use of
a second tier level of test will take place in the
future.
Quantitative Correlation between
Mutagenicity and Carcinogenicity
The qualitative correlation between mutagenic-
ity and carcinogenicity makes it possible to identify
carcinogenic chemicals with short-term mutagenic-
ity tests. But at some point we have to deal with
the quantitative side ofthe problem; that is, does a
high mutation rate of a compound correspond to a
high cancer risk? This is a far more complicated
problem.
Attempts have been made to study the correla-
tion between the mutagenicity potency in the Sal-
monella test and the cancerpotency in animal tests.
Theresults have notbeenparticularly encouraging.
Although a correlation has been found for many
chemicals, as in an analysis by Meselson and Rus-
sell (20), there are many examples of chemicals
where little or no correlation seems to exist. As a
matter offact this is what could be expected when
oneconsidersthemechanismofinduction oftumors.
It is generally recognized that cancer is induced in
at least two steps: initiation and promotion. The
mechanisms for initiation and promotion are clearly
different, and only the initiation step seems to
involve a mutation event. Mutagenicity tests there-
fore reflect only the first step in cancer induction.
Cancer tests in animals, on the other hand, usually
measure complete carcinogenicity of single com-
pounds, which means that the compound acts both
as aninitiator and promotor. A correlation between
mutagenicityandcarcinogenicitycanonlybeexpected
if there is a complete correspondence between the
initiating and the promoting ability of the test
compounds, and that is most certainly not the case.
It is therefore unlikely that mutation and cancer
will show any consistent quantitative correlation.
For a reasonably reliable quantification of the
cancerrisk, one is still largely dependent on animal
cancer data, as Bartsch and Tomatis emphasize in
their working paper (22). But I think it is appropri-
ate to point out that animal cancer data are mostly
obtained with single chemicals, which again implies
a simplification of the real situation for human
populations, which are exposed to complex mix-
tures of initiating and promoting agents.
Some Future Aspects
of Mutagenicity Testing
The short-term tests have indeed developed into
veryimportant tools totrace carcinogenic and muta-
genic hazards. But it is hoped that this develop-
ment has not come to an end, and I would like to
finish by pointing out some areas, where I think
further research is needed.
One such area concerns induced mutations in
quantitative characters. There are two aspects of
thatproblem. Theordinarymutationassays, whether
ofbacteria, fungi, cell cultures ormammals, alltake
into consideration only that type ofmutation which
implies acomplete inactivation ofthe gene function.
But all the mutations whichjust cause a decrease of
the gene function are not picked up in the test
systems, in spite of the fact that such mutations
presumably are the most common ones.
The other aspectofquantitative mutagenic effects
concerns polygenes, that is manycooperatinggenes
determining one character, as opposed to major
genes, which are the ones studied in ordinary muta-
genicity tests. Few organisms have been studied in
this respect, but data from Drosophila are ofinter-
est and relevance in this connection (21). Firstly,
investigations of viability and fitness in Drosophila
have indicated that polygenic mutations are far
more common than major mutations. Secondly, the
data indicate that the mutation frequency per gene
ismuch higherforpolygenes thanformajorgenes-
whatever the molecular mechanism of that can be.
Thirdly, polygenic mutations tend to have an unex-
pectedly strong effect in heterozygous condition.
All these data point to the possibility that such
polygenes constitute a class of genes, which some-
how differ from major genes and also respond
differently to mutagenic agents. Of particular con-
cern is the fact that traits like mental ability and
speed ofreaction in humans must largely be deter-
mined by polygenes. By restricting our tests to
major genes in mutagenicity screening we may in
fact be dealing just with the top of an iceberg.
An important aspect of mutagenicity screening
for the detection of carcinogenicity concerns the
relation between initiation of cancer and mutation.
Although the evidence strongly points to the fact
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that cancer is initiated by some kind ofa mutagenic
event, theactualnature ofthateventisnotknown-
whether it involves point mutations, chromosomal
aberrations, transpositions, DNA methylations or
possibly other DNA alterations. The frequency of
the initiating eventintumorformation isalso obscure,
particularly because ofthe multistep nature ofcan-
cer induction. The potency between chemicals for
induction of mutations and cancer may, however,
be of some interest in this connection. For cancer
the potency varies in the order of 107 (22). Iftumor
induction requires at least two successive steps,
initiation and promotion, the initiating step ought
to exhibit an even higher variation in potency, as
the promoting step must imply a restriction in
tumor formation. It is, however, ofinterest to note
that data of Bartsch et al. (22,23) rather may indi-
cate a more narrow range of potency for single
point mutations than for cancer with a given set of
chemicals. If this indeed were to be the case, it
must be concluded that the initiation of tumors
either involves a large number of loci or else that
the mutagenic event is not comparable to point
mutations, but occurs at a higher rate.
There have been specific suggestions of other
mechanisms for initiation ofcancer than "ordinary"
mutations, such as an effect on the methylation
process involved in cellular differentiation (24) and
transpositions ofDNA segments (25). The transpo-
sition hypothesis isinteresting because ofits resem-
blance to the viral induction of cancer. However,
there is no experimental support for transpositions
being involved in induced cancer-in fact carcino-
genic agents do not seem to affect transpositions
neither in prokaryotes, nor in eukaryotes, such as
Drosophila (26,27).
Concerning the actual interaction with carcino-
gens and the genetic material Ames has suggested
that radical formation may play an essential role in
tumor induction, both for initiation and for promo-
tion. He has furthermore suggested that the com-
paratively low cancer frequency in humans is the
result ofthe fact that man and primates in general
possess a unique radical scavenger in uric acid in
the blood (28). Investigations of the role of radical
reactions in carcinogenesis and mutagenesis will
probably requirethe development ofnewtechniques,
as exemplified by Ames synthesis of new Salmo-
nella strains which are sensitive to peroxides.
Thepotentiality ofincreasingthepredictive value
ofshort term tests to human carcinogenicity proba-
bly to a large extent rests on future basic research
concerning the actual mechanism of initiation and
promotion. A better understanding of these pro-
cesses will greatly pave the way for more relevant
test systems and a safer extrapolation to humans.
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